Prospective Controlled Cohort Study of the Incidence, Trajectory, and Clinical Correlates of Persistent Systemic Symptoms in Women With and Without Silicone Breast Implants
3. september 2026 oppdatert av: Research Inc
This prospective controlled cohort will enroll women before primary aesthetic breast surgery.
Women receiving silicone implants will be compared with women undergoing nonimplant mastopexy or reduction.
Standardized systemic symptom, psychosocial, quality-of-life, and local breast assessments will be collected before surgery and through five years.
The primary outcome is the incidence of a prespecified, adjudicated persistent new-onset multisystem symptom phenotype.
Revision, explantation, local implant complications, and symptom changes after implant removal will also be evaluated.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Detaljert beskrivelse
The study addresses limitations of revision-only registry analyses by measuring symptoms before any implant exposure, including a contemporaneous nonimplant surgical control group, and applying a prespecified research phenotype rather than relying only on surgeon judgment or participant-requested BII labeling.
Both cohorts will complete the same validated symptom and psychosocial battery at baseline, during early recovery, and annually through five years.
Persistent cases will undergo multidisciplinary adjudication and clinically appropriate evaluation for alternative diagnoses.
Implant complications, revision indications, and device characteristics will be recorded.
A nested subcohort will measure symptom trajectories before and after explantation or exchange.
Studietype
Observasjonsmessig
Registrering (Antatt)
3000
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Juan Velez, MD, Plastic surgeon
- Telefonnummer: +57 301 6918526
- E-post: info@velezlara.com
Studiesteder
-
-
-
Medellín, Colombia
- Rekruttering
- IQ interquirofanos
-
Ta kontakt med:
- juan Velez, MD, Plastic surgeon
- Telefonnummer: +57 321 8119802
- E-post: direccion.medica@iqinterquirofanos.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Adult women planning primary aesthetic breast surgery, enrolled before receiving silicone implants or before a nonimplant breast procedure such as mastopexy or reduction.
Beskrivelse
Inclusion Criteria:
- Female sex and age 18 years or older.
- Planning primary aesthetic breast augmentation with silicone implants or planning nonimplant aesthetic breast surgery such as mastopexy or reduction.
- No prior permanent breast implant.
- Completion of the full baseline systemic-symptom and psychosocial assessment before surgery.
- Ability to participate in annual follow-up for five years.
- Written informed consent.
Exclusion Criteria:
- Breast reconstruction after cancer, prophylactic mastectomy, congenital deformity, or major trauma.
- Known active autoimmune, inflammatory, neurologic, endocrine, infectious, or malignant condition expected to cause major systemic symptom change, unless the final protocol intentionally includes and stratifies these conditions.
- Current pregnancy or breastfeeding.
- Prior permanent breast implant or tissue expander.
- Inability to complete validated questionnaires in the authorized language.
- Planned simultaneous major surgery expected to dominate systemic recovery beyond the prespecified postoperative window.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Silicone Breast Implant Cohort
Women who independently choose primary aesthetic augmentation with silicone implants after standard counseling.
|
Implant characteristics include manufacturer/lot when available, texture, shape, volume, pocket plane, incision route, and laterality.
Exposure is chosen as clinical care before enrollment and is not assigned by the study.
Linked arm/group(s): Silicone Breast Implant Cohort.
A locked battery will include validated measures of fatigue, pain interference, cognitive function, physical function, anxiety, depression, global health, and breast/body satisfaction.
Proposed instruments include PROMIS short forms and BREAST-Q scales, subject to final licensing and language validation.
Linked arm/group(s): Silicone Breast Implant Cohort, Nonimplant Breast Surgery Control Cohort.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of an Adjudicated Persistent New-Onset Multisystem Symptom Phenotype
Tidsramme: 10 years
|
Proportion of participants who develop new or clinically meaningful worsening in at least two prespecified systemic symptom domains, persisting for at least 6 months, beginning after the initial 3-month postoperative recovery window, and not better explained by an alternative diagnosis after blinded adjudication.
The final domain list and thresholds will be locked before enrollment.
|
10 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Revision or Explantation Attributed to Systemic Symptoms
Tidsramme: 10 years
|
Proportion undergoing implant exchange or explantation for participant-reported systemic symptoms or clinician-recorded BII/ASIA indication, reported separately from local complications and elective aesthetic reasons.
|
10 years
|
|
Change in Systemic Symptom Burden After Explantation or Exchange
Tidsramme: 10 years
|
Within-person change in the prespecified symptom and PROM scores from the pre-revision assessment to 3, 6, and 12 months after explantation or exchange.
|
10 years
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: juan velez, MD, plastic surgery
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Ribeiro PDC, Sato EI. Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone. Clin Rheumatol. 2022 Nov;41(11):3275-3283. doi: 10.1007/s10067-022-06274-0. Epub 2022 Jul 7.
- Ferreira S, Barros AS, Marques M. Breast Implant Illness: Symptoms, Outcomes with Explantation and Potential Etiologies-A Systematic Review and Meta-analysis. Aesthetic Plast Surg. 2025 Dec;49(23):6600-6620. doi: 10.1007/s00266-025-05142-x. Epub 2025 Aug 11.
- Spit KA, Scharff M, de Blok CJ, Niessen FB, Bachour Y, Nanayakkara PW. Patient-reported systemic symptoms in women with silicone breast implants: a descriptive cohort study. BMJ Open. 2022 Jun 9;12(6):e057159. doi: 10.1136/bmjopen-2021-057159.
- Tervaert JWC, Shoenfeld Y, Cruciani C, Scarpa C, Bassetto F. Breast implant illness: Is it causally related to breast implants? Autoimmun Rev. 2024 Jan;23(1):103448. doi: 10.1016/j.autrev.2023.103448. Epub 2023 Sep 13.
- Shivarov V, Yordanov A, Ivanova M, Tsoneva E. Breast Implant Illness and Autoimmune/Inflammatory Syndrome Induced by Adjuvants: Mechanistic Rationale and a Practical Multidisciplinary Diagnostic Algorithm. J Clin Med. 2026 Jul 21;15(14):5721. doi: 10.3390/jcm15145721.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
12. januar 2014
Primær fullføring (Faktiske)
1. januar 2026
Studiet fullført (Antatt)
15. desember 2026
Datoer for studieregistrering
Først innsendt
3. september 2026
Først innsendt som oppfylte QC-kriteriene
3. september 2026
Først lagt ut (Faktiske)
9. september 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 024
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
no contempled in the patient informed concent
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .